A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC).
AUTHORS
Jovanovic
B ,
Mayer
IA ,
Mayer
EL ,
Abramson
VG ,
Bardia
A ,
Sanders
M ,
Kuba
MG ,
Estrada
MV ,
Beeler
JS ,
Shaver
TM ,
Johnson
KN ,
Sanchez
V ,
Rosenbluth
JM ,
Dillon
PM ,
Forrero-Torres
A ,
Chang
JC ,
Meszoely
I ,
Grau
A ,
Lehmann
BD ,
Shyr
Y ,
Sheng
Q ,
Chen
SC ,
Arteaga
CL ,
Pietenpol
JA ,
. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 3 7; ().
- NIHMSID: 9502500
ABSTRACT
Due to inherent disease heterogeneity, targeted therapies have eluded TNBC, and biomarkers predictive of treatment response have not yet been identified. This study was designed to determine if the mTOR inhibitor everolimus with cisplatin and paclitaxel would provide synergistic anti-tumor effects in TNBC.
Due to inherent disease heterogeneity, targeted therapies have eluded TNBC, and biomarkers predictive of treatment response have not yet been identified. This study was designed to determine if the mTOR inhibitor everolimus with cisplatin and paclitaxel would provide synergistic anti-tumor effects in TNBC.
Tags: Faculty Publications 2017